Enanta Pharmaceuticals Inc
$
85.81
-11.54 (-11.85%)
| Volume: | 721,020 | Avg Vol (1m): | 192,453 |
| Market Cap $: | 1.69 Bil | Enterprise Value $: | 1.32 Bil |
| P/E (TTM): | 23.10 | P/B: | 4.15 |
| Earnings Power Value | 24.79 |
| Net Current Asset Value | 18.9 |
| Tangible Book | 20.69 |
| Projected FCF | 45.89 |
| Median P/S Value | 88.99 |
| Graham Number | 41.61 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1486.57 |
Cash-To-Debt ranked
higher than
78.66%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ENTA:
1486.57
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 242.82, Med: 1275.97, Max: 10000
Current: 1486.57
|
| Equity-to-Asset | 0.95 |
Equity-to-Asset ranked
higher than
94.63%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ENTA:
0.95
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -2.03, Med: 0.95, Max: 0.96
Current: 0.95
|
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 46.59 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.77 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 90.4%
WACC 11.49%
| ||
Profitability & Growth : 9/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 35.75 |
Operating Margin ranked
higher than
96.84%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ENTA:
35.75
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 23.94, Med: 39.77, Max: 77.17
Current: 35.75
|
| Net Margin % | 33.28 |
Net Margin ranked
higher than
94.44%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ENTA:
33.28
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 17.23, Med: 34.82, Max: 72.14
Current: 33.28
|
| ROE % | 19.95 |
ROE ranked
higher than
95.05%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ENTA:
19.95
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -8.51, Med: 11.41, Max: 41.05
Current: 19.95
|
| ROA % | 18.86 |
ROA ranked
higher than
96.68%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ENTA:
18.86
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 5.83, Med: 22.36, Max: 178.65
Current: 18.86
|
| ROC (Joel Greenblatt) % | 152.34 |
ROC (Joel Greenblatt) ranked
higher than
97.10%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ENTA:
152.34
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 132.61, Med: 503.76, Max: 9914.23
Current: 152.34
|
| 3-Year Total Revenue Growth Rate | 8.70 |
3-Year Revenue Growth Rate ranked
higher than
81.72%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ENTA:
6.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -46.1, Med: 9.1, Max: 28.7
Current: 6.3
|
| 3-Year Total EBITDA Growth Rate | -10.40 |
3-Year EBITDA Growth Rate ranked
higher than
61.97%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ENTA:
-12.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -53.6, Med: 1.6, Max: 19.8
Current: -12.4
|
| 3-Year EPS w/o NRI Growth Rate | -5.20 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
75.62%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ENTA:
-5.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -12.75, Max: 39.4
Current: -5.2
|
» ENTA's 30-Y Financials
Financials (Next Earnings Date: 2019-08-07)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ENTA
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2835 |
| Compare | SZSE:002287 NAS:BOLD NAS:ARWR BOM:539268 NAS:XNCR NAS:MDGL NAS:ZGNX OCSE:ALK B NAS:ALLK NAS:ZLAB NAS:ATRA NAS:ORTX NAS:RGNX SZSE:300294 NAS:RUBY NYSE:CBM XKRX:006280 TSE:4592 NAS:CORT NAS:ALEC |
| Traded in other countries | 9EP.Germany |
| Address | 500 Arsenal Street, Watertown, MA, USA, 02472 |
| Enanta Pharmaceuticals Inc is an American biotechnology company focused on research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are: hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of the company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 23.10 |
PE Ratio ranked
higher than
59.27%
of
248
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ENTA:
23.1
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 5.17, Med: 21.95, Max: 57.59
Current: 23.1
|
| PE Ratio without NRI | 23.10 |
PE without NRI ranked
higher than
59.26%
of
243
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ENTA:
23.1
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 5.17, Med: 21.95, Max: 57.59
Current: 23.1
|
| Price-to-Owner-Earnings | 24.19 |
Price-to-Owner-Earnings ranked
lower than
72.41%
of
145
companies
in the
Biotechnology
industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
ENTA:
24.19
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 16.64, Med: 36.38, Max: 155.57
Current: 24.19
|
| PB Ratio | 4.15 |
PB Ratio ranked
lower than
56.03%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ENTA:
4.15
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.55, Med: 3.3, Max: 7.42
Current: 4.15
|
| PS Ratio | 7.72 |
PS Ratio ranked
higher than
50.55%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ENTA:
7.72
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.32, Med: 7.98, Max: 121.58
Current: 7.72
|
| Price-to-Free-Cash-Flow | 20.45 |
Price-to-Free-Cash-Flow ranked
lower than
52.63%
of
152
companies
in the
Biotechnology
industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ENTA:
20.45
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 2.47, Med: 20.47, Max: 124.31
Current: 20.45
|
| Price-to-Operating-Cash-Flow | 19.41 |
Price-to-Operating-Cash-Flow ranked
lower than
60.95%
of
210
companies
in the
Biotechnology
industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ENTA:
19.41
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 2.4, Med: 19.42, Max: 76.05
Current: 19.41
|
| EV-to-EBIT | 15.78 |
EV-to-EBIT ranked
higher than
64.75%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ENTA:
15.78
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -41.1, Med: 8.1, Max: 42.1
Current: 15.78
|
| EV-to-EBITDA | 15.23 |
EV-to-EBITDA ranked
higher than
61.57%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ENTA:
15.23
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -48.8, Med: 7.9, Max: 41.4
Current: 15.23
|
| EV-to-Revenue | 5.58 |
EV-to-Revenue ranked
higher than
64.33%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ENTA:
5.58
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: -2.2, Med: 7.1, Max: 122.9
Current: 5.58
|
| PEG Ratio | 1.17 |
PEG Ratio ranked
lower than
100.00%
of
115
companies
in the
Biotechnology
industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
ENTA:
1.17
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 0, Med: 0, Max: 1.17
Current: 1.17
|
| Current Ratio | 20.68 |
Current Ratio ranked
higher than
89.11%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ENTA:
20.68
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 8.25, Med: 20.82, Max: 36.75
Current: 20.68
|
| Quick Ratio | 20.68 |
Quick Ratio ranked
higher than
89.20%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ENTA:
20.68
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 8.25, Med: 20.82, Max: 36.75
Current: 20.68
|
| Days Sales Outstanding | 61.82 |
Days Sales Outstanding ranked
lower than
74.10%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ENTA:
61.82
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 2.27, Med: 23.94, Max: 118.72
Current: 61.82
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.20 |
3-Year Share Buyback Rate ranked
higher than
89.96%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ENTA:
-1.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -92.2, Med: -5.15, Max: -0.9
Current: -1.2
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.15 |
Price-to-Tangible-Book ranked
higher than
52.24%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ENTA:
4.15
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.56, Med: 3.22, Max: 7.27
Current: 4.15
|
| Price-to-Projected-FCF | 1.87 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
52.85%
of
193
companies
in the
Biotechnology
industry.
Industry Max: 117, Med: 3.12, Min: 0.09
ENTA:
1.87
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.29, Med: 1.97, Max: 3.3
Current: 1.87
|
| Price-to-Median-PS-Value | 0.96 |
Price-to-Median-PS-Value ranked
lower than
71.83%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ENTA:
0.96
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 1.07, Max: 14.92
Current: 0.96
|
| Price-to-Graham-Number | 2.06 |
Price-to-Graham-Number ranked
lower than
56.00%
of
200
companies
in the
Biotechnology
industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
ENTA:
2.06
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 0.76, Med: 1.61, Max: 2.81
Current: 2.06
|
| Earnings Yield (Joel Greenblatt) % | 6.34 |
Earnings Yield (Greenblatt) ranked
higher than
91.58%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ENTA:
6.34
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -16.8, Med: 4.85, Max: 39.2
Current: 6.34
|
More Statistics
| Revenue (TTM) (Mil) $ | 233.98 |
| EPS (TTM) $ | 3.72 |
| Beta | 1.41 |
| Volatility % | 45.96 |
| 52-Week Range $ | 64.09 - 127.77 |
| Shares Outstanding (Mil) | 19.67 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |
» More articles for ENTA
Headlines
Log In